Developer docs
API playgroundTry for free, no card

Search company profiles

Eularis

Full company profile

uuid000f3mk

Namestring
Eularis
Legal namestring
Eularis Limited
Websiteurl
eularis.com
Company typeenum
Private
Founded yearint
2003
Descriptiontext

Eularis is a privately held strategy and governance advisory firm focused exclusively on biopharma and life sciences organizations. Founded in 2003 by Dr. Andrée Bates, the firm is headquartered in London with offices in New York and operates across the US, UK, Switzerland, Japan, and Australia. It does not sell AI software; instead it sells the strategic, governance, and human foundation that makes AI work in FDA-regulated pharma environments.

The firm's core offering is organized around four entry points — AI Strategy, AI Governance (a three-tier program covering Assessment, Foundation, and Managed Service aligned to FDA, EMA, EU AI Act, ISO 42001, and NIST AI RMF), Strategic AI Intelligence (The Bates Briefing), and AI Capability Building (Pharma AI Institute and the AI For Pharma Leaders Masterclass). These are supported by three service modules: REVEAL Lab (AI-powered commercial problem solving), ACCELERATE Lab (foundational readiness for AI projects), and the Transformation Engine (future-proof strategy). Proprietary methodologies are a key technical component, even though no software product is shipped.

Revenue is generated through professional services engagements (board-level advisory capped at 4-6 active relationships, AI Strategy Diagnostic Sprints, Strategic Assessments, and full AI Strategic Blueprints), training programs and speaking engagements, and two subscription streams (AI-cademy membership and The Bates Briefing). Pricing is not publicly disclosed. Named enterprise customers include Pfizer, Merck Japan, Novo Nordisk, Takeda Pharmaceuticals, and Eurocine Vaccines. The firm is bootstrapped with no disclosed external funding, no public listing, and no M&A activity, with founder involvement remaining central to client delivery.

Short descriptiontext

Eularis is a private biopharma AI strategy and governance advisory firm founded in 2003, serving pharmaceutical, biotechnology, and hospital network clients globally. It sells consulting engagements, board-level advisory, training programs, and subscription memberships rather than AI software, with deep regulatory expertise across FDA, EMA, and EU AI Act frameworks.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical AI consulting, biopharma AI strategy, AI governance advisory, pharma regulatory AI, pharmaceutical sales analytics
Industry3 codes
PRIMARYBPAEAHAJ
Responsible AI, AI Governance & Compliance Services
SECONDARYHDAAAMAE
Regulatory Readiness & Audit Automation (e.g., EU AI Act, NIST AI RMF, ISO/IEC 42001)
SECONDARYHDAEANAE
Enterprise AI Governance, Risk & Compliance Platforms (Model Risk, Audit, Policies)
Hardware, Technology & Telecom/Enterprise Platforms & Databases/Artificial Intelligence Platforms for Enterprise
NAICS code1 code
  • Management, Scientific, and Technical Consulting Services5416
SIC code1 code
  • Services-Computer Programming, Data Processing, Etc.7370
Product category
Pharmaceutical AI Consulting
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model5 records
1Strategic Consulting Engagements
TypeProfessional Services
Description

AI Strategy and Governance consulting engagements including AI Strategy Diagnostic Sprint (2-week engagement), Strategic Assessment, and full AI Strategic Blueprint development with corporate financial modelling

eularis.com
2AI-cademy Membership
TypeSubscription Recurring
Description

Subscription membership providing success pathways, resources, tools, big data access, CEO roundtables, and personalized support for healthcare leaders. Monthly and annual billing options available

eularis.com
3AI Training Programs
TypeProfessional Services
Description

AI For Pharma Leaders Masterclass (2-day intensive training), Pharma AI Institute, virtual live training, and speaking engagements for conferences and internal events

eularis.com
4Board-Level Advisory
TypeProfessional Services
Description

Dr. Bates provides board-level advisory to small number of pharma and biotech companies on AI strategy, governance, and capital allocation (limited to 4-6 active relationships)

eularis.com
5The Bates Briefing
TypeSubscription Recurring
Description

Strategic AI intelligence publication for pharma leadership - written analysis, monthly videos, quarterly reports and exec sessions

eularis.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Marketing or Sales, Technology or R&D
Pricing details4 tiers
1AI-cademy Membership - Monthly
ModelSubscriptionBilling cadenceMonthly
Notes

Monthly subscription with access to success pathways, resources, tools, big data, and community. Cancel anytime from inside account.

eularis.com
2AI-cademy Membership - Annual
ModelSubscriptionBilling cadenceAnnual
Notes

Annual subscription with 365 days access. Can cancel automatic renewal at any time.

eularis.com
3AI Strategy Diagnostic Sprint
ModelOtherBilling cadenceMulti-year contract
Notes

2-week focused engagement including up to five stakeholder interviews. Fee credited in full to AI Strategic Blueprint if proceeding within 30 days.

eularis.com
4AI For Pharma Leaders Masterclass
ModelSubscriptionBilling cadenceMulti-year contract
Notes

Exclusive two-day training program available as Masterclass, Enterprise License, or virtual live training format

eularis.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 5 records shown
1AI-cademy
Description

Membership platform providing AI training and resources for healthcare leaders, including success pathways, big data access, and CEO roundtables on AI.

eularis.com
+4 more records
Core offering1 text field

Eularis is a strategic AI consulting and advisory firm that guides pharmaceutical, biotechnology, and large healthcare organizations through AI strategy, governance, and capability building. The firm delivers board-defensible AI governance frameworks aligned with FDA, EMA, EU AI Act, ISO 42001, and NIST AI RMF, along with AI strategy diagnostic sprints, executive advisory, and AI training programs. Rather than selling AI tools, Eularis builds the strategic and human foundations that make AI adoption succeed in regulated biopharma environments.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • 0% of launch drugs Eularis has worked on have become top brands within 1 year
+1 more record
Product overview1 text field

Eularis is a strategic AI consulting and advisory firm for biopharma and life sciences organisations, offering a portfolio of services rather than a single software product. The core offering includes four main entry points: AI Strategy (identifying optimal AI paths for impact), AI Governance (board-defensible governance frameworks covering FDA, EMA, EU AI Act, ISO 42001, NIST AI RMF), Strategic AI Intelligence (The Bates Briefing - written analysis and reports by Dr. Andrée Bates), and AI Capability Building (Pharma AI Institute training). These are supplemented by three service labs: REVEAL LAB (solving complex commercial challenges), ACCELERATE LAB (foundational project elements), and TRANSFORMATION ENGINE (future-proofing strategy). Additional offerings include the AI-cademy membership platform, AI Mentoring, the AI Strategy Diagnostic Sprint, the AI For Pharma Leaders Masterclass, AI Speaking Engagements, and the AI For Pharma Growth Podcast. The company does not sell AI tools but builds strategic and human foundations for AI adoption.

Product and service1 record
1AI Strategy
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-12
Description

Dr. Andrée Bates (founder of Eularis) serves as an inaugural member of DrugBank's Advisory Board to guide AI adoption in the biopharma industry. DrugBank positions structured, expert-validated data as the foundation biopharma organizations need to ensure AI credibility in scientific and medical workflows. The board addresses the gap between record-level AI investment and lagging data infrastructure within a 12-month window.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global strategy consulting firm with a healthcare and life sciences practice serving pharma commercial strategy and AI-driven transformation — comparable in serving top pharma on strategy, broader in scope.

2Trinity Partners
TypeDirect peer
Description

Specialized strategy consulting firm for life sciences, focused on commercial strategy and analytics for pharma and biotech — directly comparable boutique peer with similar therapeutic-area and commercial strategy focus.

3ZS Associates
TypeDirect peer
Description

Global consulting firm deeply focused on pharma and biopharma sales, marketing, and analytics — directly comparable to Eularis in serving pharma commercial strategy and AI-driven analytics buyers, with significantly larger scale.

TypeBroad incumbent
Description

Global consulting firm with a dedicated life sciences practice serving pharma and biotech strategy, economics, and analytics — comparable in serving pharma strategy and commercial analytics buyers, with broader corporate scope.

TypeDirect peer
Description

Specialized healthcare and life sciences strategy consulting firm focused on pharma, biotech, and medical technology — directly comparable niche consultancy serving similar pharma strategy buyers.

TypeBroad incumbent
Description

Large health communications and commercialization services group serving pharma commercial, marketing, and AI-driven engagement — comparable in serving pharma commercial and marketing analytics buyers as part of a wider commercialization portfolio.

TypeBroad incumbent
Description

Large life sciences technology and analytics provider offering commercial strategy, real-world evidence, and AI/data services to pharma — comparable in serving pharma commercial and analytics buyers but at vastly greater scale and breadth.

TypeBroad incumbent
Description

Global management consultancy with a major pharma and medical products practice — comparable in delivering AI strategy and governance to pharma leadership, though as part of a much broader consulting portfolio.

TypeBroad incumbent
Description

Global professional services firm with a dedicated life sciences practice delivering digital, data, and AI strategy — comparable in serving large pharma on AI strategy and digital transformation, but at much larger scale and as part of broader services.

TypeDirect peer
Description

Life sciences strategy consulting firm serving pharma and biotech commercial strategy and access engagements — directly comparable niche consultancy with overlapping pharma commercial and market access expertise.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Eularis

Pharmaceutical AI Consultingeularis.com

Eularis is a private biopharma AI strategy and governance advisory firm founded in 2003, serving pharmaceutical, biotechnology, and hospital network clients globally. It sells consulting engagements, board-level advisory, training programs, and subscription memberships rather than AI software, with deep regulatory expertise across FDA, EMA, and EU AI Act frameworks.

What Eularis does

Eularis is a privately held strategy and governance advisory firm focused exclusively on biopharma and life sciences organizations. Founded in 2003 by Dr. Andrée Bates, the firm is headquartered in London with offices in New York and operates across the US, UK, Switzerland, Japan, and Australia. It does not sell AI software; instead it sells the strategic, governance, and human foundation that makes AI work in FDA-regulated pharma environments.

The firm's core offering is organized around four entry points — AI Strategy, AI Governance (a three-tier program covering Assessment, Foundation, and Managed Service aligned to FDA, EMA, EU AI Act, ISO 42001, and NIST AI RMF), Strategic AI Intelligence (The Bates Briefing), and AI Capability Building (Pharma AI Institute and the AI For Pharma Leaders Masterclass). These are supported by three service modules: REVEAL Lab (AI-powered commercial problem solving), ACCELERATE Lab (foundational readiness for AI projects), and the Transformation Engine (future-proof strategy). Proprietary methodologies are a key technical component, even though no software product is shipped.

Revenue is generated through professional services engagements (board-level advisory capped at 4-6 active relationships, AI Strategy Diagnostic Sprints, Strategic Assessments, and full AI Strategic Blueprints), training programs and speaking engagements, and two subscription streams (AI-cademy membership and The Bates Briefing). Pricing is not publicly disclosed. Named enterprise customers include Pfizer, Merck Japan, Novo Nordisk, Takeda Pharmaceuticals, and Eurocine Vaccines. The firm is bootstrapped with no disclosed external funding, no public listing, and no M&A activity, with founder involvement remaining central to client delivery.

Eularis firmographics

Firmographics
Name
Eularis
Legal name
Eularis Limited
Website
https://eularis.com
Company type
Private
Founded year
2003
Operating status
Operating
Headcount range
1–10 employees
Short description
Eularis is a private biopharma AI strategy and governance advisory firm founded in 2003, serving pharmaceutical, biotechnology, and hospital network clients globally. It sells consulting engagements, board-level advisory, training programs, and subscription memberships rather than AI software, with deep regulatory expertise across FDA, EMA, and EU AI Act frameworks.
Ownership category
akta.pro rank

Eularis industry classification

Industry
Product category
Pharmaceutical AI Consulting
NAICS
Management, Scientific, and Technical Consulting Services (5416)
SIC
Services-Computer Programming, Data Processing, Etc. (7370)
akta.pro industry
PRIMARYBPAEAHAJ
Responsible AI, AI Governance & Compliance Services
SECONDARYHDAAAMAE
Regulatory Readiness & Audit Automation (e.g., EU AI Act, NIST AI RMF, ISO/IEC 42001)
SECONDARYHDAEANAE
Enterprise AI Governance, Risk & Compliance Platforms (Model Risk, Audit, Policies)
Hardware, Technology & Telecom/Enterprise Platforms & Databases/Artificial Intelligence Platforms for Enterprise

Keywords

  • Pharmaceutical AI consulting
  • Biopharma AI strategy
  • AI governance advisory
  • Pharma regulatory AI
  • Pharmaceutical sales analytics

Where Eularis is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

Eularis business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D

Revenue model

  1. Strategic Consulting Engagements: AI Strategy and Governance consulting engagements including AI Strategy Diagnostic Sprint (2-week engagement), Strategic Assessment, and full AI Strategic Blueprint development with corporate financial modelling
  2. AI-cademy Membership: Subscription membership providing success pathways, resources, tools, big data access, CEO roundtables, and personalized support for healthcare leaders. Monthly and annual billing options available
  3. AI Training Programs: AI For Pharma Leaders Masterclass (2-day intensive training), Pharma AI Institute, virtual live training, and speaking engagements for conferences and internal events
  4. Board-Level Advisory: Dr. Bates provides board-level advisory to small number of pharma and biotech companies on AI strategy, governance, and capital allocation (limited to 4-6 active relationships)
  5. The Bates Briefing: Strategic AI intelligence publication for pharma leadership - written analysis, monthly videos, quarterly reports and exec sessions

Pricing tiers

ModelBillingPrice
SubscriptionMonthlyAI-cademy Membership - Monthly
SubscriptionAnnualAI-cademy Membership - Annual
OtherMulti-year contractAI Strategy Diagnostic Sprint
SubscriptionMulti-year contractAI For Pharma Leaders Masterclass

Go-to-market motion3 records

Distribution channels4 records

Marketing channels7 records

Eularis product offering

Product offering

Core offering

Eularis is a strategic AI consulting and advisory firm that guides pharmaceutical, biotechnology, and large healthcare organizations through AI strategy, governance, and capability building. The firm delivers board-defensible AI governance frameworks aligned with FDA, EMA, EU AI Act, ISO 42001, and NIST AI RMF, along with AI strategy diagnostic sprints, executive advisory, and AI training programs. Rather than selling AI tools, Eularis builds the strategic and human foundations that make AI adoption succeed in regulated biopharma environments.

Product overview

Eularis is a strategic AI consulting and advisory firm for biopharma and life sciences organisations, offering a portfolio of services rather than a single software product. The core offering includes four main entry points: AI Strategy (identifying optimal AI paths for impact), AI Governance (board-defensible governance frameworks covering FDA, EMA, EU AI Act, ISO 42001, NIST AI RMF), Strategic AI Intelligence (The Bates Briefing - written analysis and reports by Dr. Andrée Bates), and AI Capability Building (Pharma AI Institute training). These are supplemented by three service labs: REVEAL LAB (solving complex commercial challenges), ACCELERATE LAB (foundational project elements), and TRANSFORMATION ENGINE (future-proofing strategy). Additional offerings include the AI-cademy membership platform, AI Mentoring, the AI Strategy Diagnostic Sprint, the AI For Pharma Leaders Masterclass, AI Speaking Engagements, and the AI For Pharma Growth Podcast. The company does not sell AI tools but builds strategic and human foundations for AI adoption.

Differentiator

Problem solved

Functional benefit

Brands

  • AI-cademy: Membership platform providing AI training and resources for healthcare leaders, including success pathways, big data access, and CEO roundtables on AI.
  • The Bates Briefing
  • Reveal Lab
  • Accelerate Lab
  • Transformation Engine

Products and services

  • AI Strategy

Quantifiable outcome

  • 0% of launch drugs Eularis has worked on have become top brands within 1 year
  • +1 more outcomes

Companies that use Eularis

Customer profile

Named customers5 records

Segments4 records

Ideal customer profiles3 records

Eularis technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Eularis partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • DrugBankcoreStrategic or Co-development Partner · 12 May 2026Dr. Andrée Bates (founder of Eularis) serves as an inaugural member of DrugBank's Advisory Board to guide AI adoption in the biopharma industry. DrugBank positions structured, expert-validated data as the foundation biopharma organizations need to ensure AI credibility in scientific and medical workflows. The board addresses the gap between record-level AI investment and lagging data infrastructure within a 12-month window.

Scale indicators5 records

Recent moves5 records

Expansion highlights6 records

Eularis competitors and assessment

Company assessment

Broad incumbents

  • Bain & Company (Healthcare & Life Sciences): Global strategy consulting firm with a healthcare and life sciences practice serving pharma commercial strategy and AI-driven transformation — comparable in serving top pharma on strategy, broader in scope.
  • Charles River Associates (Life Sciences practice): Global consulting firm with a dedicated life sciences practice serving pharma and biotech strategy, economics, and analytics — comparable in serving pharma strategy and commercial analytics buyers, with broader corporate scope.
  • Inizio Evoke (formerly known as Ashfield Health / Real Chemistry): Large health communications and commercialization services group serving pharma commercial, marketing, and AI-driven engagement — comparable in serving pharma commercial and marketing analytics buyers as part of a wider commercialization portfolio.
  • IQVIA: Large life sciences technology and analytics provider offering commercial strategy, real-world evidence, and AI/data services to pharma — comparable in serving pharma commercial and analytics buyers but at vastly greater scale and breadth.
  • McKinsey & Company (Pharma & Medical Products practice): Global management consultancy with a major pharma and medical products practice — comparable in delivering AI strategy and governance to pharma leadership, though as part of a much broader consulting portfolio.
  • Accenture (Life Sciences): Global professional services firm with a dedicated life sciences practice delivering digital, data, and AI strategy — comparable in serving large pharma on AI strategy and digital transformation, but at much larger scale and as part of broader services.

Direct peers

  • Trinity Partners: Specialized strategy consulting firm for life sciences, focused on commercial strategy and analytics for pharma and biotech — directly comparable boutique peer with similar therapeutic-area and commercial strategy focus.
  • ZS Associates: Global consulting firm deeply focused on pharma and biopharma sales, marketing, and analytics — directly comparable to Eularis in serving pharma commercial strategy and AI-driven analytics buyers, with significantly larger scale.
  • Health Advances: Specialized healthcare and life sciences strategy consulting firm focused on pharma, biotech, and medical technology — directly comparable niche consultancy serving similar pharma strategy buyers.
  • Putnam Associates: Life sciences strategy consulting firm serving pharma and biotech commercial strategy and access engagements — directly comparable niche consultancy with overlapping pharma commercial and market access expertise.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Eularis social profiles

Digital presence

Eularis financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Eularis leadership team

Management profile

Number of profiles

Profiles1 record

Eularis funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Eularis M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Eularis

What does Eularis do?

Eularis is a strategic AI consulting and advisory firm that guides pharmaceutical, biotechnology, and large healthcare organizations through AI strategy, governance, and capability building. The firm delivers board-defensible AI governance frameworks aligned with FDA, EMA, EU AI Act, ISO 42001, and NIST AI RMF, along with AI strategy diagnostic sprints, executive advisory, and AI training programs. Rather than selling AI tools, Eularis builds the strategic and human foundations that make AI adoption succeed in regulated biopharma environments.

Is Eularis a public or private company?

Eularis is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Eularis founded?

Eularis was founded in 2003. It employs 1 to 10 people.

Where is Eularis based?

Eularis is headquartered in London, United Kingdom, in the Europe region.

How does Eularis make money?

Five revenue lines are on record. Strategic Consulting Engagements are the primary driver. The others are AI-cademy Membership, AI Training Programs, board-Level Advisory and the Bates Briefing.

Who are Eularis's main competitors?

Broad incumbents on record are Bain & Company (Healthcare & Life Sciences), Charles River Associates (Life Sciences practice), Inizio Evoke (formerly known as Ashfield Health / Real Chemistry), IQVIA, McKinsey & Company (Pharma & Medical Products practice) and Accenture (Life Sciences). Direct peers are Trinity Partners, ZS Associates, Health Advances and Putnam Associates.

Does Eularis have an API?

No public API is recorded for Eularis.

What industry is Eularis in?

Eularis's product category is Pharmaceutical AI Consulting. Its primary akta.pro industry code is BPAEAHAJ, Responsible AI, AI Governance & Compliance Services, with a secondary code of HDAAAMAE, Regulatory Readiness & Audit Automation (e.g., EU AI Act, NIST AI RMF, ISO/IEC 42001). Its NAICS code is 5416 and its SIC code is 7370.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
LinkedInAI-based Supply Chain Optimization To Cut Costs In PharmaAn opinion piece by Dr. Andrée Bates of Eularis argues that AI-based supply chain optimization can cut costs in the pharmaceutical industry, citing McKinsey's finding that inefficiencies can raise supply chain costs by up to 30%. It cites Novo Nordisk, AstraZeneca and Pfizer, with savings of $20 million annually, 40% lower inventory carrying costs and 25% higher efficiency.News-MedicalEULAR develops new recommendations for cardiovascular risk managementEULAR developed new recommendations for cardiovascular risk management in people with rheumatic and musculoskeletal diseases, including gout, vasculitis, and lupus. The taskforce produced 19 recommendations split into two groups, covering prediction tools, traditional risk factors, and disease-related factors. The advice aims to guide clinical practice and future research.PR NewswirePharma companies gain competitive advantage from 1 day Masterclass on Artificial Intelligence in Pharma sales and marketingEularis, a pharmaceutical analytics company, announced the release of a one-day Masterclass on using Artificial Intelligence to transform pharma sales and marketing, scheduled for September 9, 2016 in New York and September 23, 2016 in London. The company states that many pharma sales and marketing teams do not understand AI's relevance to their roles, and that applying these technologies creates a strong competitive advantage in a difficult pharma market. Founded in 2003, Eularis has worked with clients including Boehringer Ingelheim, Merck, Pfizer, Roche, and Shire, and claims to be the first company offering this level of sophisticated machine learning tools for the pharmaceutical industry.